Compound ID | 3396
Reltecimod
Synonym(s): AB103 | AB 103 | AB-103 | p2TA
Class: Immunomodulator agent
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against Staphylococcus aureus; intended indication forS. aureus necrotizing soft tissue infection, acute kidney injury, and peritonitis; attenuates inflammatory response of hosts from pathogen infections by binding to superantigens interfering their ability to bind CD28 or binding directly to CD28 (interference with CD28 signalling prevents release of cytokines) |
| Description: | Synthetic oligopeptide; shows homology to CD28 residues; antagonizes interaction with CD28 on T cells |
| Institute where first reported: | Atox Bio |
| Year first mentioned: | 2011 |
| Highest developmental phase: | Phase 3 (NCT03403751) |
| Development status: | Terminated |
| Reason Dropped: | Poor enrolment of patients during clinical trial |
| External links: | |
| Main Source: | https://access.portico.org/Portico/auView?auId=ark:%2F27927%2Fpjbf78x6tds |
| Citation: | https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1001149 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.